Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2001-11-30
2008-09-09
Fetterolf, Brandon J (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S135100, C424S152100, C424S184100
Reexamination Certificate
active
07422738
ABSTRACT:
Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.
REFERENCES:
patent: 4837003 (1989-06-01), Nicolotti
patent: 4925922 (1990-05-01), Byers et al.
patent: 5296467 (1994-03-01), Reutelingsperger
patent: 5344758 (1994-09-01), Krilis et al.
patent: 5382427 (1995-01-01), Plunkett et al.
patent: 5627036 (1997-05-01), Reutelingsperger
patent: 5632986 (1997-05-01), Tait et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5658877 (1997-08-01), Tsao
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5677181 (1997-10-01), Parish
patent: 5725856 (1998-03-01), Hudziak et al.
patent: 5767298 (1998-06-01), Daleke
patent: 5776427 (1998-07-01), Thorpe et al.
patent: 5830448 (1998-11-01), Vehar
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5863538 (1999-01-01), Thorpe et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5874081 (1999-02-01), Parish
patent: 5877289 (1999-03-01), Thorpe et al.
patent: 5922688 (1999-07-01), Hung et al.
patent: 5965132 (1999-10-01), Thorpe et al.
patent: 6004554 (1999-12-01), Thorpe et al.
patent: 6004555 (1999-12-01), Thorpe et al.
patent: 6020153 (2000-02-01), Hardman et al.
patent: 6036955 (2000-03-01), Thorpe et al.
patent: 6043094 (2000-03-01), Martin et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 6057435 (2000-05-01), Godowski et al.
patent: 6093399 (2000-07-01), Thorpe et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6197278 (2001-03-01), Blankenberg et al.
patent: 6300308 (2001-10-01), Schroit
patent: 6312694 (2001-11-01), Thorpe et al.
patent: 6333348 (2001-12-01), Vogel et al.
patent: 6406693 (2002-06-01), Thorpe et al.
patent: 6783760 (2004-08-01), Thorpe et al.
patent: 6806354 (2004-10-01), Schroit
patent: 6818213 (2004-11-01), Thorpe et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 7067109 (2006-06-01), Thorpe et al.
patent: 2002/0025319 (2002-02-01), Brams
patent: 2003/0004097 (2003-01-01), Schroit
patent: 2003/0228625 (2003-12-01), Toh et al.
patent: 2005/0113297 (2005-05-01), Francois et al.
patent: 0 458 878 (1996-09-01), None
patent: 0 669 988 (2003-09-01), None
patent: WO 91/07187 (1991-05-01), None
patent: WO 93/17715 (1993-09-01), None
patent: WO 95/19791 (1995-07-01), None
patent: WO 95/27903 (1995-10-01), None
patent: WO 95/34315 (1995-12-01), None
patent: WO 96/01653 (1996-01-01), None
patent: WO 96/17618 (1996-06-01), None
patent: WO 97/17084 (1997-05-01), None
patent: WO 98/04294 (1998-02-01), None
patent: WO 98/29453 (1998-07-01), None
patent: WO 98/43678 (1998-10-01), None
patent: WO 01/54723 (2001-08-01), None
patent: WO 01/68709 (2001-09-01), None
Fishman et al (International Journal of Oncology, 10, 901-904, May 1997).
Tschmelitsch et al. (Cancer Research 57, 2181-2186, Jun. 1, 1997).
Hillman et al. (Cell Immunol. 1995; 160: 257-263).
Jain (Scientific American Jul. 1994).
Dillman (Annals of Internal Medicine, vol. 111, pp. 592-603, 1989).
Weiner (Seminars Oncology, vol. 26, No. 4, 1999, pp. 41-50).
Ran et al. (Cancer Research 2002; 62: 6132-6140).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4).
Dermer (Bio/Technology, 1994, 12:320).
Jordan et al. (J. Emergency Nursing 1991; 17: 8-10).
Symons et al (Medical Hypotheses 2001; 57: 56-58).
Campbell, A.M. (Monoclonal Antibody Technology, Elsevier Science, NY, 1986, pp. 1-33).
Holash et al (Oncogene 1999; 18: 5356-5362).
Einzig et al. (Investigational New Drugs 1991; 9: 59-64).
O'Reilly et al. (Cell 1997; 88: 277-285, published Jan. 24, 1997).
Wolff et al. (Cancer research 1993; 53: 2560-2565).
Moossa, A.R., Schimpff, S.C., Robson, M.C.. (Comprehensive Textbook of Oncology, Baltimore, Maryland, 1991).
Contag and Bachmann, “The Writing is on the Vessel Wall,”Nature, 429:618-619, 2004.
Oh et al., “Subtractive Proteomic Mapping of the Endothelial Surface in Lung and Solid Tumours for Tissue-Specific Therapy,”Nature, 429:629-635, 2004.
Wang et al., “The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis,”J. Can. Res. Clin. Oncol., 124(11):615-620, 1998 (Abstract only).
Adler et al., “Monoclonal Antiphosphatidylserine Antibody Inhibits Intercellular Fusion of the Choriocarcinoma Line, JAR”,Biology of Reproduction, 53:905-910, 1995.
Bakimer et al., “Antiphospholipid Syndrome and the Idiotypic Network,”Lupus, 4(3):204-208, 1995 (Abstract only).
Fishman et al., “Vitiligo Autoantibodies are Effective Against Melanoma,”Cancer, 72:2365-2369, 1993.
Hosomi et al., “Simple Purification Method of the Antiphospholipid Antibody from Normal Human Plasma,”Exp. Clin. Immunogenet., 14:281-285, 1997.
Miyazawa et al., “Monoclonal Antibody Analysis of Phosphatidylserine and Protein Kinase C Localizations in Developing Rat Cerebellum,”J. Neurochem., 59:1547-1554, 1992.
Reza et al., “Anti-Idiotypic Monoclonal Antibody Recognizes a Consensus Recognition Site for Phosphatidylserine in Phosphatidylserine-Specific Monoclonal Antibody and Protein Kinase C,”FEBS Lett., 339:229-233, 1994.
International Search Report for PCT/US01/07895, mailed Jun. 6, 2001.
Ezzell et al., “Cancer “Vaccines”: An Idea Whose Time Has come?,”J. NIH Research, 7:46-49, 1995.
Thorpe, “Vascular Targeting Agents as Cancer Therapeutics,”Clin. Can. Res., 10:415-427, 2004.
Hardman et al., In Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition, pp. 51 and 57-58, 1996.
Becker and Brocker, “Antiphospholipid Syndrome Associated with Immunotherapy for Patients with Melanoma,”Cancer, 75:2785, 1995.
Bevers et al., “Changes in Membrane Phospholipid Distribution During Platelet Activation,”Biochim. Biophys. Acta., 122:429-436, 1982.
Connor et al., “Exposure of Phosphatidylserine in the Outer Leaflet of Human Red Blood Cells,”J. Biol. Chem., 736:57-66, 1983.
Fadok et al., “Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages,”J. Immunol., 148:2207-2216, 1992.
Katsuragawa et al., “Monoclonal Antiphosphatidylserine Antibody Reactivity Against Human First-Trimester Placental Trophoblasts,”Am. J. Obstetr. Gynecol., 172:1592-1597, 1995.
Maneta-Peyret et al., “Demonstration that Anti-Phospholipid Auto-Antibodies React with Both Anionic and Zwitterionic Phospholipids,”Immunol. Lett., 35:141-146, 1993.
Naldi et al., “Antiphospholipid Antibodies and Melanoma: A Link?,”Dermatology, 184:156, 1992.
Rote et al., “Expression of Phosphatidylserine-Dependent Antigens on the Surface of Differentiating BeWo Human Choriocarcinoma Cells,”Am. J. Rep. Immunol., 33:114-121, 1995.
Zwaal and Schroit, “Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells,”Blood, 89:1121-1132, 1997.
Katsuragawa et al., “Monoclonal Antibody Against Phosphatidylserine Inhibits In Vitro Human Trophoblastic Hormone Production and Invasion,”Biology Reproduction, 56:50-58, 1997.
Lin et al., “Monoclonal IgM Antiphosphatidylserine Antibody Reacts Against Cytoskeleton-Like Structures in Cultured H
Ran Sophia
Thorpe Philip E.
Board of Regents , The University of Texas System
Fetterolf Brandon J
Fussey Shelley P. M.
LandOfFree
Combined cancer treatment methods using antibodies to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined cancer treatment methods using antibodies to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined cancer treatment methods using antibodies to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3990878